What is Progenra?
Progenra is a biopharmaceutical company dedicated to pioneering novel medicines through the strategic targeting of the Ubiquitin Proteasome System (UPS). Leveraging its proprietary UbiPro platform, Progenra specializes in molecular glues and targeted protein degradation to engineer first-in-class therapeutics. The company's research and development efforts are focused on addressing critical unmet needs across several therapeutic domains, including neurodegenerative diseases, cardiovascular disorders, and metabolic dysfunction. Progenra's objective is to revolutionize treatment paradigms and enhance patient outcomes through its advanced drug discovery engine, actively pursuing strategic collaborations to accelerate its pipeline of transformative therapies.
How much funding has Progenra raised?
Progenra has raised a total of $330K across 2 funding rounds:
Debt
$150K
Debt
$180K
Debt (2020): $150K with participation from PPP
Debt (2021): $180K led by PPP
Key Investors in Progenra
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Progenra?
With substantial late-stage funding, Progenra is well-positioned to accelerate the clinical development of its pipeline candidates and further validate its UbiPro platform. The company's focus on targeted protein degradation aligns with emerging trends in drug discovery, suggesting a strong potential for market disruption. Future strategic investments will likely be directed towards expanding its therapeutic reach, forging key partnerships for commercialization, and scaling its operational capacity to meet the demands of late-stage drug development. Progenra's commitment to innovation in addressing complex diseases underscores its potential for significant growth and impact in the biopharmaceutical sector.
See full Progenra company page
